Bronchiectasis is one of the most common highly heterogeneous chronic inflammatory airway diseases in China. It has a long course, heavy symptom burden, and is prone to recurrent acute exacerbations, ...

In March 2025, The Lancet Respiratory Medicine published a phase 2 clinical study article on China's first DPP-1 inhibitor, HSK31858, led by Academician Nan-shan Zhong and Professor Wei-jie Guan from ...

Please provide your email address to receive an email when new articles are posted on . The relationship between blood eosinophil count and bronchiectasis severity was U-shaped, meaning greater ...

Targeting airway inflammation with investigational brensocatib reduced exacerbations with bronchiectasis, the ASPEN trial showed. The dipeptidyl peptidase 1 (DPP-1) inhibitor cut the annualized rate ...

Bronchiectasis is a heterogeneous condition and may be encountered as a stand-alone pulmonary disease by primary care clinicians and specialists in pulmonary medicine. Bronchiectasis sometimes ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Bronchiectasis ...

Results of a large, global clinical trial spanning five continents with over 1,700 patients with bronchiectasis, published this April in the New England Journal of Medicine, demonstrated benefits of ...

Mucoactive agents did little to stave off pulmonary exacerbations of non-cystic fibrosis bronchiectasis, the CLEAR trial showed. In the two-by-two factorial trial testing hypertonic saline and ...

Mark Metersky, MD, FCCP, illustrates the pathology of bronchiectasis. This is a video synopsis/summary of an Insights involving Mark Metersky, MD, FCCP, on bronchiectasis. Bronchiectasis is an ...